Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Board asks insurance committee to study GLP-1 drug costs after spike in cash prices
Summary
Board members flagged recent retail prices for GLP-1 drugs (Wegovy/Ozempic) and asked the district insurance committee and Brown & Brown to evaluate coverage options to reduce employee and district pharmacy spend; staff said options will be proposed to the insurance committee and returned to the board.
At the workshop, board members raised concern about sharply lower cash retail prices for GLP-1 drugs and potential impacts on the district's health-care spend. One board member noted new cash prices of about $200 for initial months and $350 thereafter and asked whether the district could lower its costs by adjusting insurance or using an outside…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
